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Appropriate Evaluation and
Treatment of Heart Failure Patients After
Implantable Cardioverter-Defibrillator Discharge
Time to Go Beyond the Initial Shock
Joseph D. Mishkin, MD,* Sherry J. Saxonhouse, MD,* Gregory W. Woo, MD,*
Thomas A. Burkart, MD,* William M. Miles, MD,* Jamie B. Conti, MD,*
Richard S. Schofield, MD,* Samuel F. Sears, PHD,† Juan M. Aranda, JR, MD*
Gainesville, Florida; and Greenville, North Carolina
Multiple clinical trials support the use of implantable cardioverter-defibrillators (ICDs) for prevention of sudden
cardiac death in patients with heart failure (HF). Unfortunately, several complicating issues have arisen from the
universal use of ICDs in HF patients. An estimated 20% to 35% of HF patients who receive an ICD for primary
prevention will experience an appropriate shock within 1 to 3 years of implant, and one-third of patients will ex-
perience an inappropriate shock. An ICD shock is associated with a 2- to 5-fold increase in mortality, with the
most common cause being progressive HF. The median time from initial ICD shock to death ranges from
168 to 294 days depending on HF etiology and the appropriateness of the ICD therapy. Despite this progno-
sis, current guidelines do not provide a clear stepwise approach to managing these high-risk patients. An
ICD shock increases HF event risk and should trigger a thorough evaluation to determine the etiology of the
shock and guide subsequent therapeutic interventions. Several combinations of pharmacologic and device-
based interventions such as adding amiodarone to baseline beta-blocker therapy, adjusting ICD sensitivity,
and employing antitachycardia pacing may reduce future appropriate and inappropriate shocks. Aggressive
HF surveillance and management is required after an ICD shock, as the risk of sudden cardiac death is
transformed to an increased HF event risk. (J Am Coll Cardiol 2009;54:1993–2000) © 2009 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.039m
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gore than 200,000 patients with heart failure (HF) have
eceived an implantable cardioverter-defibrillator (ICD) to
educe their risk of sudden cardiac death since 2005, when
he last of the HF ICD prevention trials was published
1,2). Since the original American College of Cardiology/
merican Heart Association/North American Society of
acing and Electrophysiology 2002 guidelines introduced
he concept of ICDs as primary prevention therapy for
atients with left ventricular dysfunction and myocardial
nfarction, subsequent updated practice guidelines have
xpanded ICD indications to include patients with nonische-
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ccepted July 12, 2009.ic cardiomyopathy, an ejection fraction 35%, and New
ork Heart Association (NYHA) functional class II or III
F (3–5). Current practice guidelines are based on several
rospective multicenter clinical trials that support the use of
CD therapy to reduce the risk of sudden death in a wide
ariety of HF patients (6–10).
Data from 6,000 patients enrolled in clinical trials have
evealed several complicating issues arising from the univer-
al use of ICDs in HF patients (Table 1). Twenty percent to
5% of HF patients who receive an ICD for primary
revention will receive an appropriate shock within 1 to 3
ears for a life-threatening arrhythmia (11,12). Forty-five
ercent of HF patients who survive a cardiac arrest and
eceive an ICD for secondary prevention will receive a shock
ithin 1 year of implant (9). The incidence of inappropriate
hock in the HF ICD population is as high as 27%, with an
verall annual shock rate of 7.5% (11).
Among HF patients, an ICD shock is associated with a 2-
o 5-fold increase in mortality, most commonly due to pro-
ressive HF (11). It is not known whether the arrhythmia
eading to ICD shock is a marker for worsening HF or
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Heart Failure Management After ICD Shock November 24, 2009:1993–2000whether the shock itself leads to
worsening HF. Subgroup analyses
from MADIT-II (Multicenter
Automatic Defibrillator Implanta-
tion Trial II) confirm that ICD
shocks increase the risk for first
and recurrent HF events (9,13).
Despite the risks associated
with an ICD shock, current
practice guidelines do not offer a
clear stepwise approach to the
evaluation and treatment of HF
patients who experience their
initial ICD shock. This review
describes an evidence-based,
multidisciplinary strategy for
evaluating and managing HF pa-
tients who receive an ICD shock,
with special emphasis on aggres-
sive monitoring to reduce future
shocks and HF events.
F Prognosis After ICD Discharge
lthough physicians are commonly relieved that sudden
ardiac death was prevented after an ICD shock, current
ata suggest that the natural history of the disease is now
ransformed. The MADIT-II investigators first described
he issue of worsening prognosis after ICD therapy (6).
fter an ICD shock for a life-threatening arrhythmia,
ospitalizations for HF were more frequent, and mortality
as increased 3-fold (13). Within 1 year of an ICD shock
or ventricular tachycardia (VT) or ventricular fibrillation
VF), the probability of an HF event was 26% and 31%,
espectively, while it was 19% for those not having an ICD
13). Survival rate was 80% 1 year after initial ICD shock for
T or VF. Survival curves were related to the rate of the
resenting tachycardia. Increased tachycardia rates were
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
AF  atrial fibrillation
ATP  antitachycardia
pacing
AV  atrioventricular
HF  heart failure
ICD  implantable
cardioverter-defibrillator
NYHA  New York Heart
Association
RV  right ventricular
SVT  supraventricular
tachycardia
VF  ventricular fibrillation
VT  ventricular
tachycardia
ummary of ICD Therapy and HF Events in Major Trials*Table 1 Summary of ICD Therapy and HF Events in Major Trials
AVID 1997
Number of patients with ICDs 492
Follow-up, months 18
Ejection fraction, median 32%
Primary vs. secondary prevention Secondary
ISCM vs. NISCM 81% ISCM
19% NISCM
Proportion of patients receiving shocks 45% (12 months)
62% (24 months)
Appropriate shock 39% (12 months)
Inappropriate shock 20%
Successful antitachycardia pacing delivery 63% at 12 months
77% at 24 months
HF hospitalizations and events after ICD 60%‡
Implantable cardioverter-defibrillator (ICD) trials with follow-up information regarding frequency of
ppropriate and inappropriate shocks. ‡All-cause rehospitalization.
ISCM  ischemic cardiomyopathy; NISCM  nonischemic cardiomyopathy.ssociated with lower survival rates. Other clinical factors
ssociated with increased mortality after appropriate ICD
ischarge were blood urea nitrogen 25 mg/dl, lack of
eta-blockade, greater NYHA functional class, presence of
trial fibrillation (AF), and diabetes mellitus (13,14). Sub-
equent analysis demonstrated that ICD therapy was asso-
iated with a 39% increased risk of a first HF hospitalization
nd a 58% increase in recurrent admission for HF (13).
Analysis of the SCD-HeFT (Sudden Cardiac Death in
eart Failure Trial) data (11) showed findings similar to
hose of the MADIT-II study. In the SCD-HeFT study,
3% of HF patients received an ICD shock, and among
hose patients, the most common cause of death was
rogressive HF. Patients receiving an appropriate shock had
5-fold increase in risk of death, whereas patients receiving
n inappropriate shock had a 2-fold increase in risk of death.
ultiple shocks (1) further increased the risk of death.
he median time from shock to death was 168 days among
atients receiving appropriate shocks and 294 days among
atients receiving inappropriate shocks. Similar to MADIT-II
atients, SCD-HeFT patients with NYHA functional class III
nd ischemic cardiomyopathy had a shorter duration between
nitial shock and death.
There is much debate as to why ICD patients tend to
ave worsening prognosis and more frequent HF after an
CD shock. Myocardial damage induced by ICD shocks
ay contribute to decompensated HF (15). In the
ADIT-II study, however, inappropriate shocks did not
ncrease the risk of worse outcomes. In the SCD-HeFT
tudy, mortality after an inappropriate shock was 3-fold less
han after appropriate therapy, thus downplaying the role of
hock-induced myocardial damage contributing to HF risk,
nd suggesting that arrhythmia may simply be a marker of
lready-worsening HF. Others report that right ventricular
RV) pacing with a dual-chamber ICD may contribute to
ncreased HF risk after ICD implant (16). In the
ADIT-II study, however, the risk of HF events was
MADIT-II 2002 DEFINITE 2004 SCD-HeFT 2005
719 227 811
20 29 45
30% 21% 25%
Primary Primary Primary
100% ISCM 100% NISCM 52% ISCM
48% NISCM
29% (22 months) 40% (29 months) 33% (45 months)
14.1% 18% 16%†
11.5% 21% 11%
48% — Not programmed
23% (24 months) — 42% (HF deaths)
riate and inappropriate ICD therapy and heart failure (HF) events. †An additional 7% received both*
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November 24, 2009:1993–2000 Heart Failure Management After ICD Shockimilar whether patients received a single- or dual-chamber
CD despite differences in RV pacing (92% of patients
ith single-lead ICDs had no pacing, whereas 66% of
atients with dual-chamber ICDs had cumulative RV
acing exceeding 50%) (13). Therefore, the increased risk
f HF after ICD implantation cannot be solely due to RV
acing.
Regardless of the individual factors causing greater HF
vents in current ICD populations, there appear to be
ultiple triggers that, when combined with high-risk pa-
ients (whose lives are saved by appropriate ICD therapy),
ause an increased HF risk. Heart failure patients with
igh-risk features such as NYHA functional class III, AF,
nd ischemic cardiomyopathy require closer observation and
anagement after ICD shock as sudden death risk is now
ransformed to an increased HF event risk.
valuation of HF After ICD Discharge
he initial evaluation of the HF patient who receives an
CD shock begins with interrogation of the device (Fig. 1).
he timing of the device interrogation depends on the
Figure 1 Algorithm for Evaluation and Management of ICD Sho
Evaluation of implantable cardioverter-defibrillator (ICD) shock based on time fram
strategies. AF  atrial fibrillation; HF  heart failure; IV  intravenous; SVT  supumber of shocks and related symptoms. If an HF patient
eceives 1 isolated shock without change in clinical status or
ymptoms, evaluation should generally occur within 1 week
17,18). This evaluation can occur in the form of a clinic
isit or review of downloaded home telemetry from the ICD
hat can provide diagnostic information. There may be
otentially reversible causes such as electrolyte abnormalities
hat should be checked and corrected to prevent possible
ecurrence that could lead to future shocks. Thyroid func-
ion should also be measured, and a thorough review of
otentially exacerbating medication should be undertaken.
he rate of recurrent inappropriate shocks is as high as 43%
11). ICD shocks accompanied by worsening HF symp-
oms, syncope, angina, or electrical storm warrant emer-
ency medical attention (17).
Device interrogation will reveal whether the ICD shock
as appropriate or inappropriate. The definition of an
ppropriate shock is controversial. Some argue that with
urrent antitachycardia pacing (ATP) algorithms, a shock
or VT may be appropriate but unnecessary. For the purpose
f this review, any shock for VT or VF is considered
etiology of shock, with current suggested management
ricular tachycardia; VF  ventricular fibrillation; VT  ventricular tachycardia.ck
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Heart Failure Management After ICD Shock November 24, 2009:1993–2000ppropriate. This definition is similar to the criteria used in
eviews of major ICD trials (2,7,19).
nappropriate shock. Inappropriate ICD shocks account
or 10% to 24% of ICD discharges (20). Causes of inap-
ropriate shocks include AF, supraventricular tachycardia
SVT), oversensing (i.e., QRS and T-wave double count-
ng), and mechanical problems such as lead fracture, insu-
ation break, and lead dislodgement. Heart failure patients
ho receive inappropriate shocks tend to be younger and
ore likely to have AF. They have less coronary artery
isease, and their HF is more advanced (17–19,21,22). The
ost common cause of an inappropriate ICD shock is AF
r SVT with rapid ventricular conduction, with an incidence
f 15% to 18% (19). Large HF databases suggest that the
verall incidence of AF in HF patients is 10% to 50%,
aking the potential of inappropriate detection a significant
roblem (23). Because initial device detection of VT or VF
s based on the ventricular rate, SVT with rapid ventricular
esponse may fall into a device’s programmed VT or VF
one with subsequent delivery of inappropriate therapy
Fig. 2). Various algorithms that address morphology, sta-
ility, and onset of tachycardia have been developed to
ifferentiate between VT and SVT (24). The continued
roblem of VT/VF therapy delivered for SVT may reflect a
eluctance to activate detection-enhancement algorithms,
hich have the potential to underdetect VT or VF and may
esult in the delay or suppression of appropriate therapy
25). When studied in clinical trials, many of these algo-
ithms have had a limited effect in reducing inappropriate
herapies. In some cases, this is due to the “time out”
unction that overrides SVT discriminators when arrhyth-
ia is persistent.
Pharmacologic therapy can be used to reduce inappropri-
te shocks caused by AF and SVT. Despite the abundance
f data regarding the benefits of beta-blocker therapy in HF
26–28), beta-blocker therapy alone has not been shown to
Figure 2 Example of Inappropriate Shock for Atrial Fibrillation
A heart failure patient with a dual-chamber implantable cardioverter-defibrillator rec
(single arrow). The ventricular electrogram reveals fast and irregular activity. The d
marker channel. An inappropriate shock was delivered (double arrow). AS and S 
with an inhibited pacing mode (the pacing mode after shock); HV  high voltage; Veduce inappropriate shocks, perhaps because doses used
ay not have provided adequate control of AF with fast
entricular response (29). Nevertheless, the OPTIC (Opti-
al Pharmacological Therapy in Cardioverter Defibrillator
atients) study demonstrated that inappropriate shocks
mostly for SVT) were significantly reduced by amiodarone
lus beta-blocker therapy (30).
Oversensing can also lead to inappropriate shocks, spe-
ifically when the device incorrectly detects more ventricular
ctivity than is actually present. This can occur from both
ntracardiac and extracardiac sources. Two common intra-
ardiac sensing problems are T-wave oversensing and QRS
ouble counting. The incidence of T-wave oversensing
ccounting for inappropriate shocks is3% (31). Oversens-
ng of T waves can be transient and triggered by exercise or
lectrolyte abnormalities (Fig. 3). This problem can often be
orrected with device reprogramming. The sensitivity level
f the device can be changed so that only the appropriate
entricular signal is sensed by the device. In addition,
djusting the refractory period (interval after ventricular
ensed event in which the device is essentially “blind”) may
lso help prevent abnormal sensing of T waves. When
rogramming changes make a device less sensitive, defibril-
ation testing is recommended to ensure that the device still
etects ventricular arrhythmias. Oversensing of T waves
hat cannot be overcome with reprogramming may be due
o suboptimal lead position, and placement of a new
ace-sense lead may be required.
Extracardiac sensing can arise from skeletal myopoten-
ials, electromagnetic interference, or mechanical lead prob-
ems including fracture, dislodgement, and insulation break.
lead fracture (incidence 1% to 4%), should be suspected in
he HF patient presenting with multiple shocks in rapid
uccession (32). Interrogation of the device will demonstrate
change in lead impedance and often a failure to sense or
apture appropriately. Software upgrades are available to
multiple shocks. The atrial electrogram demonstrated atrial fibrillation
recognized the rate in the ventricular fibrillation zone, shown as “F” in the
l sensed events; DDI  non-P-synchronous dual chamber pacing and sensing
entricular sensed events.eived
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November 24, 2009:1993–2000 Heart Failure Management After ICD Shocklosely monitor leads that may be susceptible to fracture.
nfortunately, lead failures cannot be resolved with simple
evice reprogramming. Tachyarrhythmia detection algo-
ithms usually need to be turned off to prevent inappropriate
hocks, and the patient needs to be observed in a closely
onitored setting until the lead can be revised or replaced.
ppropriate shock. Twenty-two percent to 35% of pa-
ients will receive appropriate ICD therapy for VT or VF
ithin 3 years of implant (11,12), with an annual ICD
hock rate of 5%. Whether a patient with VT receives an
CD shock or ATP will depend on device algorithm
rogramming. The SCD-HeFT study was designed to
rovide ICD therapy that consisted of shock-only, single-
ead therapy for rapid, sustained VT or VF. No dual-
hamber or ATP therapy was allowed. The incidence of
ppropriate shock for VT or VF was 22.4%. Sixty-seven
ercent of patients received no ICD therapy. In the
ADIT-II study, dual-chamber devices were used with the
apability of ATP or shock therapy. With 59% of patients
Figure 3 Example of Inappropriate Shock for T-Wave Oversensi
A patient with a dual-chamber ICD presented with frequent ICD shocks. (A) The in
plot shows a 1:1 atrioventricular ratio (single arrow). Fifteen seconds before dete
rates. (B) An intracardiac electrogram shows the device detecting the T waves as
inappropriate shock. The patient was subsequently found to be hyperkalemic. Abbaving ATP activated, 281 episodes of VT were terminated Vy ATP in 147 patients, and 305 episodes of VT were
erminated by ICD shock in 108 patients (12). Three years
fter ICD implant, 35% of patients had received appropriate
herapy for VT or VF.
ATP therapies painlessly interrupt re-entrant ventric-
lar arrhythmias using brief, rapid bursts of pacing.
ntitachycardia pacing is routinely used to terminate
lower ventricular arrhythmias (188 beats/min) with
fficacy of 90% and a low risk (5%) of accelerating
ower VT rates leading to eventual shock. The Pain-
REE Rx II (Pacing Fast Ventricular Tachycardia Re-
uces Shock Therapies II) study evaluated the efficacy of
TP for fast ventricular arrhythmias in 634 patients (33).
ompared to shock therapy, ATP for fast arrhythmias
as highly effective and safe, with improvement in both
hysical and emotional well-being as well as in social
unctioning. In a more recent study of primary prevention
atients (34), there was significant reduction in ICD
hocks during the first year of follow-up with strategic
plot demonstrates atrial and ventricular cycle length over time. The initial interval
double arrows) reveals a classic “train track” pattern of 2 ventricular sensing
ular events (see marker channel), interpreting the episode as VF, resulting in an
ns as in Figure 1.ng
terval
ction (
ventric
reviatioT/VF detection programming.
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Heart Failure Management After ICD Shock November 24, 2009:1993–2000Pharmacologic therapy for appropriate shocks includes
nstitution of standard HF therapy such as angiotensin-
onverting enzyme inhibitors (ACEIs), statins, and beta-
lockers with the addition of antiarrhythmic medications.
CEIs and statins have both been shown to reduce atrial
nd ventricular arrhythmias (35–37). In an analysis of the
ADIT-II study, a significant reduction in ICD therapy
or VT and VF was noted in patients taking a higher dose
f beta-blocker (29). Up-titration to optimal doses of
eta-blockers should include metoprolol succinate (200 mg
aily) or carvedilol (25 mg twice daily). The appropriate
ose of ACEIs includes lisinopril equivalents between 20
nd 40 mg daily (26,27,37). These medications decrease the
ncidence of both atrial and ventricular arrhythmias (37,38).
Antiarrhythmic therapy is prescribed to 49% to 69% of
atients with an ICD (39). Adverse events such as proar-
hythmia and serious side effects leading to discontinuation
ccur in20% of patients (40). Despite this, the addition of
miodarone to beta-blockers has been shown to reduce the
isk of appropriate ICD shocks and is commonly added to
tandard HF therapy for these patients (41). Sotalol is
nother option for the prevention of ICD shocks and has
een shown to reduce the incidence of appropriate ICD
hocks in a small randomized trial (42).
The HF ICD patient presenting with recurrent appro-
riate shocks while receiving amiodarone therapy remains a
ifficult challenge. Current treatment strategies include
itrating beta-blocker therapy while simultaneously increas-
ng the dose of amiodarone. A second antiarrhythmic agent
uch as mexiletine can also be used, although there is
inimal supporting evidence in recent literature. An ICD
hould be tested after antiarrhythmic drug changes to assure
roper detection and efficacy of therapy.
reatment of Refractory Arrhythmias
f both optimization of pharmacologic therapy and device
eprogramming fail to prevent continued appropriate and
nappropriate shocks, the more invasive strategy of catheter
blation can be employed. A recent multicenter observa-
ional study demonstrated a reduction in VT in ICD
atients after myocardial infarction with the use of irrigated
adiofrequency catheter ablation (43). In addition, the
MASH-VT (Substrate Mapping and Ablation in Sinus
hythm to Halt Ventricular Tachycardia) study showed a
ignificant reduction in ICD therapy with prophylactic
atheter ablation in post-MI patients who received ICDs
or secondary prevention (44). The updated European
eart Rhythm Association/Heart Rhythm Society guide-
ines support the use of catheter ablation in symptomatic
ustained VT that persists despite antiarrhythmic drug
herapy as well as control of incessant VT storm that has no
eversible cause (45). A large number of supraventricular
rrhythmias are also amenable to this therapy. For patients
ith AF and difficult-to-control ventricular rates that leado recurrent inappropriate shocks, atrioventricular nodal
blation with biventricular pacing is a viable option (46).
Patients presenting with electrical storm, defined as 3
pisodes of hemodynamically destabilizing VTs within 24 h
47), need immediate attention and care. Electrical storm,
hich can occur in up to 20% of patients, causes a more
han 5-fold higher risk of death in the subsequent 3 months
20). Recent data suggest both short- and long-term bene-
ts with catheter ablation in these high-risk patients who
re refractory to antiarrhythmic therapy (48). If catheter
blation and antiarrhythmic medications fail, then these
atients may benefit from more advanced therapy such as
eft ventricular assist device or cardiac transplantation.
F Surveillance After ICD Shock
lthough a fair amount of evidence suggests that HF
atients who receive an ICD shock are at increased risk of
F hospitalization and HF events (12), current guidelines
o not address the need for more aggressive HF surveillance
nd management. Current ICD trials have shown that the
ime from shock to HF event is 160 to 204 days (11)
epending on the number of appropriate or inappropriate
hocks and the etiology of HF. About one-third of patients
ith ischemic cardiomyopathy will have an HF event within
year of an appropriate shock.
lan for Managing Psychosocial Distresselated to Impla table Cardi verter-Defibrillator ShockTable 2 Plan for Man ging Psychosoc al DistressRelated to Implantable Cardioverter-Defibrillator Shock
Patient and Family
Strategy Clinical Task
Shock prevention
efforts
Reassure patient that strategies to reduce shock are
in place (e.g., antitachycardia pacing, medication
change, programming specifics).
Shock education and
psychosocial
information
Discuss with patient that:
1. Living with cardiac disease has challenges, but the
patient will be able to cope with the challenges.
2. Support is available from your clinic as well as
referral for stress management and mental health.
3. Patient and family outlook involving a positive
and hopeful future is reasonable and health
promoting (51).
Re-engagement activity
plan
Short-term follow-up
Help patient and family:
1. Recognize the importance of returning to
appropriate activity level to prevent activity
avoidance.
2. Understand your expectation of return to activity.
Long-term follow-up
Health care team should:
1. Assess for signs of emotional distress or
avoidance of activity.
2. Seek cardiac rehabilitation referral for support in
return to activity (52).
Plan for future shock Discuss standard plan for managing shock in the
future (53):
1. If you get a single shock and feel fine, please call
the clinic.
2. If you get a single shock and do not feel well, seek
emergency medical care.3. If you get a second shock, seek emergency care.
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November 24, 2009:1993–2000 Heart Failure Management After ICD ShockChronic management of the HF patient after ICD shock
hould involve close surveillance throughout the following
ear for early signs and symptoms of impending decompen-
ated HF. During this time, careful monitoring for recur-
ent AF (especially in patients who received inappropriate
hocks) and titration of beta-blockers to optimal dosage
hould be undertaken. Although there are no prospective
ata that suggest these interventions will reduce HF events,
he current poor prognosis after ICD shock justifies aggres-
ive surveillance of these patients. This surveillance should
nclude a combination of more frequent clinical encounters,
itration of established HF therapy as tolerated, and close
ttention to volume status. A multidisciplinary approach
nvolving the primary care physician, the HF specialist, and
he electrophysiologist should be employed.
uality of Life
he patient and family response to ICD shocks remains an
mportant consideration during appropriate management.
CD patients may vary in their ability to tolerate multiple
hocks before reporting detectable decrements in quality of
ife (49). Regardless, an ICD shock can initiate a set of
oncerns for ICD patients and families that warrants sig-
ificant intervention.
The primary patient benefit of an ICD is achieving a
ense of security from potentially life-threatening arrhyth-
ias. An ICD shock can affect that sense of security and
lter a patient’s adjustment to HF and acceptance of the
CD. The SCD-HeFT data indicate that ICD patients had
etter psychological quality of life at 3 and 12 months after
mplantation than did amiodarone patients (50). There were
o differences between groups at 30 months in patient-
eported quality of life. This course of quality of life was
ifferent if the ICD patient had received a shock. Shocked
CD patients reported significant decrements in quality of
ife. ICD shocks create a degree of lifestyle interruption to
he patient and family. A suggested plan for managing
sychosocial distress related to ICD shock is shown in Table 2
51–53).
onclusions
CD therapy is now part of standard medical care to reduce
he risk of sudden cardiac death in HF patients. Although
60% of patients who receive an ICD for primary preven-
ion will not receive an ICD shock over the first several
ears, many will receive appropriate and inappropriate
hocks that are associated with an increase in HF event risk.
ppropriate evaluation of the HF patient after ICD shock
s required to identify the cause and reduce the incidence of
uture shocks. Heart failure surveillance strategies need to be
eveloped as patients continue to avoid sudden cardiac
eath while increasing their risk of HF events after an ICD
hock.
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